Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial

Table 3 Eradication-related adverse events, n (%)

	Tailored therapy using DPO-PCR (n = 50)	Empirical bismuth-based quadruple therapy (n = 104)	P value
Eradication-related side effects			< 0.001
No	44 (88.0)	59 (56.7)
Yes	6 (12.0)	45 (43.7)
Abdominal discomfort	0 (0.0)	1 (1.0)
Nausea/vomiting	3 (6.0)	12 (11.5)
Diarrhea/loose stool	0 (0.0)	12 (11.5)
Dyspepsia	2 (4.0)	10 (9.6)
General weakness	1 (2.0)	6 (5.8)
Taste disturbance	0 (0.0)	4 (3.8)
Treatment compliances
	50 (100.0)	100 (96.2)	0.2

DPO-PCR: Dual priming oligonucleotide polymerase chain reaction.